Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04273542). This is a study registration, not published results. Lead sponsor: Centre Jean Perrin. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 1100 participants (ESTIMATED). Conditions: Breast Cancer Female, BRCA1 Mutation, BRCA2 Mutation. Interventions: OTHER: liquid biopsy. Primary outcome measures: Validation of the value of molecular profiling analysis in broadband laser spectroscopy on liquid biopsies for breast cancer screening , Comparison between the different cohorts at (T0 : inclusion) and the others visits (T1:+1year; T2: +2years; T3 : +3years; T4:+4years; T5: 5years). Brief summary: The purpose of this study is to validate the interest of broadband spectroscopy analysis (femto/attosecond by infrared laser) on liquid biopsies in breast cancer screening.